EXHIBIT 10.81 LICENSE AGREEMENT [LY213829]

EXHIBIT 10.81

LICENSE AGREEMENT
[LY213829]

This License Agreement ("Agreement") is made as of the 5th day of November,
1996 by and between ▇▇▇ ▇▇▇▇▇ and Company, an Indiana corporation ("Lilly") and
▇▇▇▇▇▇▇ Laboratories Inc., a New Jersey corporation ("▇▇▇▇▇▇▇").

RECITALS
--------

1. Lilly and ▇▇▇▇▇▇▇ are in the business of discovering, developing and
marketing pharmaceutical products.

2. Lilly has discovered a compound internally designated as LY213829,
Tazofelone, (as defined in Section 1.02 below, the "Compound") which may be
useful in the treatment of functional gastrointestinal disorders and other
indications. Lilly has previously engaged in certain research and development
efforts including limited clinical trials with respect to the Compound, but has
concluded that future development efforts could best be conducted by a company
with a focus on gastrointestinal products.

3. ▇▇▇▇▇▇▇ desires to license from Lilly certain rights of Lilly to the
Compound and to pursue development and commercialization of the Compound within
the Territory (as defined below), and Lilly is willing to grant such license,
all upon the terms and conditions set forth in this License Agreement.

AGREEMENT
---------

In consideration of the Recitals and the mutual covenants and agreements
set forth below, the parties agree as follows:

ARTICLE 1
---------
DEFINITIONS
-----------

When used in this Agreement, each of the following terms shall have the
meanings set forth below.

Section 1.01. "Affiliate" of a party hereto means any corporation or
------------
business entity which at the time in question controls, is under common control
with, or is controlled by such party. As used herein, control shall mean the
ownership, directly or indirectly, of more than fifty percent (50%) of the
voting stock or similar interests of the corporation or business entity or the
ability to otherwise control the management of the corporation or business
entity.

-2-

Section 1.02. "Compound" means (+/-)-5-[[3,5-bis(1,1-dimethylethyl)-4-
------------
hydroxyphenyl]methyl]-4-thiazolidinone and all pharmaceutically acceptable salts
and solvates thereof.

Section 1.03. "End User" means a wholesaler, distributor, pharmacy,
------------
hospital, health care organization or patient.

Section 1.04. "Know-How" means the items listed on the attached Appendix A
------------
which are owned by or licensed to Lilly and reasonably useful to ▇▇▇▇▇▇▇ in
developing and manufacturing the Compound and Product.

Section 1.05. "Lilly Intellectual Property Rights" means all patent
------------
rights, trade secret rights, and Know-How rights owned, licensed or otherwise
controlled by Lilly as of the date hereof which encompass Compound and Product
or are useful in preparing Compound and are effective in the Territory,
including all divisions, continuations, continuations-in-part, reissuances,
reexaminations, extensions, Supplementary Protection Certificates, and any
similar intellectual property rights, and all counterparts thereof in the
Territory. A list of all patent rights owned, licensed or otherwise controlled
by Lilly as of the date hereof and which are encompassed hereunder is attached
as Appendix B.

Section 1.06. "Net Sales" means with respect to a Product, the gross
------------
amount invoiced by ▇▇▇▇▇▇▇, or any sublicensee, to an End User less the
following deductions:

1. Trade, quantity and cash discounts actually given or allowed;

2. Rebates, allowances, Medicaid and Medicare reimbursements,
chargebacks and similar deductions;

3. Any tax imposed on the sale, delivery or use of the product; and

4. Allowances or credits for returned goods or rejections of any Product
which is unsalable.

All amounts of Net Sales shall be determined from the books and records of
▇▇▇▇▇▇▇ maintained in accordance with United States generally accepted
accounting principles, consistently applied.

Section 1.07. "Phase I Clinical Trial" means a small scale clinical study
------------
conducted in normal volunteers to establish Product safety.

Section 1.08. "Phase III Clinical Trial" means a large scale clinical
------------
study conducted in patients to establish Product efficacy and to support Product
Registration.

-3-

Section 1.09. "Product" means any pharmaceutical compositon for use as a
------------
therapeutic or diagnostic product that incorporates the Compound.

Section 1.10. "Territory" means the entire world.
------------

ARTICLE II
----------
LICENSE
-------

Lilly grants to ▇▇▇▇▇▇▇ an exclusive license to make, have made, use or
sell within the Territory the Compound and Product pursuant to all Lilly
Intellectual Property Rights. With respect to any patent rights licensed
hereunder, such license shall be limited solely to those patent claims necessary
to provide ▇▇▇▇▇▇▇ with the ability to make, have made, use or sell Product
within the Territory and shall, further, be limited solely to the right to make,
have made, use or sell Product within the Territory. Such license shall include
the right of ▇▇▇▇▇▇▇ to sublicense, consistent with the terms of this Agreement.
All terms and provisions of this Agreement shall apply to each sublicense to the
same extent as they apply to ▇▇▇▇▇▇▇, and ▇▇▇▇▇▇▇ shall guarantee performance by
its sublicensee of all obligations imposed under the terms of this Agreement.

ARTICLE III
-----------
PAYMENTS AND ROYALTIES
----------------------

Section 3.01. Signing and Milestone Payments.
---------------------------------------------

(a) As consideration for the licenses granted hereunder, ▇▇▇▇▇▇▇ shall pay Lilly
by wire transfer to an account designated by Lilly the following amounts at
the following times:

(i) Upon execution of this Agreement $1 million

(ii) Upon completion of transfer of the $2 million
Know-How described in Section 1.04
of this Agreement

(iii) Upon approval of the first clinical $1 million
trial exemption or equivalent for a
Product in the United States, Canada
Japan or the European Community
(i.e., a filing such as an IND that
permits the commencement of Phase I
Clinical Trials):

-4-

(iv) Upon commencement of the first $2 million
Phase III Clinical Trial of a Product:

(v) Upon acceptance of the first New $2 million
Drug Application or similar filing in
the United States, Canada, Japan or
the European Community that seeks
permission to market a Product:

(vi) Upon approval of the first marketing $2 million
approval of a Product in the United
States, Canada, Japan or the European
Community (e.g. approval by the FDA
or similar governmental entity of an
NDA or similar filing for a Product):

(b) All payments described above shall be made within thirty (30) days of
the relevant event, except for the payment described in (a)(i), which shall be
made upon signing of this Agreement. Any payment not made when due shall bear
interest at the United States prime rate on the due date as published in the

Wall Street Journal, plus six percent (6%).
-------------------

Section 3.02. Royalty. As additional consideration for the licenses
----------------------
granted hereunder, ▇▇▇▇▇▇▇ shall pay to Lilly a royalty equal to 7% of Net Sales
of Product the Territory. Royalties shall be reported and paid quarterly in
accordance with Article VII of this Agreement.

ARTICLE IV
----------
PROSECUTION AND INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS
------------------------------------------------------------

Section 4.01. Patent Term Extension and Supplementary Protection
-----------------------------------------------------------------
Certificates. Lilly upon request of ▇▇▇▇▇▇▇ shall apply for (and ▇▇▇▇▇ ▇▇▇▇▇▇▇
------------
a license under) patent term extensions, Supplementary Protection Certificates
or functional equivalents thereof, in any jurisdication within the Territory
where usch items are permissable, for any Lilly Intellectual Property Rights
licensed to ▇▇▇▇▇▇▇ hereunder. ▇▇▇▇▇▇▇ will provide Lilly with all material and
information as may be necessary to obtain any of the aforesaid rights.

Section 4.02. Prosecution and Maintenance of Licensed Patents.
--------------------------------------------------------------

(a) Appendix B attached hereto identifies all pending patents worldwide
which are encompassed in the applications and Lilly Intellectual
Property Rights.

-5-

(b) Lilly shall prosecute any pending applications of which it is the
owner that are emcompassed in the Lilly Intellectual Property Rights
and maintain any patents that have issued or will issue thereon in
full force and effect for the term of such patent. Should, during the
course of prosecution of any pending claims, an official action
rejecting the claims require that an amendment be made or action be
taken which would limit or substantially change the scope of any
license hereunder, Lilly will timely inform ▇▇▇▇▇▇▇ in writing. Lilly
shall consult ▇▇▇▇▇▇▇ before responding to any such official action,
and allow ▇▇▇▇▇▇▇ to assist in the prosecution of such claims or, at
Lilly's option, allow ▇▇▇▇▇▇▇ to assist in the prosecution of such
claims or, at Lilly's option, allow ▇▇▇▇▇▇▇ the opportunity at its
time and expense to prosecute such claims to ▇▇▇▇▇▇▇ satisfaction.

Section 4.03. Costs of Prosecution and Maintenance of Patents. Lilly
--------------------------------------------------------------
shall bear all costs incurred in filing, prosecuting and maintaining all patents
and patent applications encompassed within he Intellectual Property Rights,
provided, however, that ▇▇▇▇▇▇▇ shall pay one-half (1/2) of all reasonable
external expenses incurred by Lilly while prosecuting and maintaining such
patents and patent applications. External expenses will include patent office
fees and taxes in connection with the prosecution and maintenance of any patent
or patent application and the fees of any patent attorneys or agents, external
of Lilly, in connection with the ex parte prosecution and maintenance thereof.
-- -----
The allocation of such expenses will occur on an annual basis at the end of the
last quarter of each calendar year, at which time Lilly will provide ▇▇▇▇▇▇▇
with an itemized list of external expenses denominated in United States dollars
incurred during the previous annual period. ▇▇▇▇▇▇▇ will then reimburse Lilly's
expenses within sixty (60) days of the date of receipt of this itemized list.
Notwithstanding the foregoing, Lilly may, at its sole discretion, choose not to
prosecute or cease to maintain a patent or patent application in any country as
it so desires and to the extent that Lilly chooses not to prosecute or ceases to
maintain such patent or patent application Lilly shall not be responsible for
any patent costs associated with prosecuting and/or maintaining the patent or
patent application in such country. If ▇▇▇▇▇▇▇ to prosecute or maintain such
patent or patent application ▇▇▇▇▇▇▇ may do so at its own expense; however,
under these circumstances, Lilly would ▇▇▇▇▇ ▇▇▇▇▇▇▇ all of its patent rights
associated with such patent in such country. Similarly, upon written notice to
Lilly, ▇▇▇▇▇▇▇ may elect not to share in the prosecution or maintenance costs as
described in this Section 4.03 related to a patent or patent application in a
particular country; however, upon such election any rights that ▇▇▇▇▇▇▇ has in
such patent in such country would be granted to Lilly.

Section 4.04 Option by ▇▇▇▇▇▇▇ to Discontinue License. ▇▇▇▇▇▇▇, at its
------------------------------------------------------
option, may elect to discontinue the license granted and surrender all rights
hereunder as to any patent on a country-by-country basis. Such election must be
made by thirty (30) days written notice by simultaneous facsimile transmission
and certified mailing,

-6-

and, with respect to the surrender of ▇▇▇▇▇▇▇' rights, will be effective as of
the date of mailing. In the event such an election is made, Lilly's obligations
under Sections 4.01 and 4.02 and ▇▇▇▇▇▇▇' obligations under Section 4.03 will
terminate thirty (30) days from the date of mailing with respect to the specific
patent on which the election is made.

Section 4.05. Infringement. Each party shall give prompt notice to the
---------------------------
other of any infringement, potential infringement or suspected infringement of
Lilly Intellectual Property Rights that may come to such party's attention.
Promptly thereafter, the parties shall consult and cooperate fully to determine
a course of action, including, but not limited to, the commencement of legal
action by one or both parties, to cause such infringement, potential
infringement or suspected infringement to be terminated. Each party, at its
option, may elect to participate in or commence such legal action. In the event
of a joint action in which both parties agree to participate, the parties will
share in the costs and the recovery of the agreed upon course of action in a
manner to be agreed upon. Failing agreement on a course of action to ▇▇▇▇▇
infringement, potential infringement or suspected infringement within sixty (60)
days of the time such infringement, potential infringement or suspected
infringement becomes known to both parties, either party shall have the right,
at its own expense, to initiate and prosecute an action against the infringer
and shall retain whatever damages are recovered. In the event ▇▇▇▇▇▇▇ is unable
to initiate and prosecute such action solely in its own name, Lilly will execute
(and cause its Affiliates to execute) all documents necessary for ▇▇▇▇▇▇▇ to
initiate and prosecute such action. Neither party will enter into any
settlement of any action referred to in this Section without the other party's
prior consent, which consent shall not be unreasonably withheld.

Section 4.06. Reexamination and Reissue. Lilly shall defend in a
----------------------------------------
reasonable manner any patent encompassed within the Lilly Intellectual Property
Rights in any reexamination or reissue proceeding in the United States Patent
and Trademark Office and the applicable foreign equivalent. Before Lilly
initiates a reissue proceeding, or before either party initiates a reexamination
proceeding, the parties shall consult as to the desirability or necessity of
such a proceeding. Such proceedings will not be abandoned prior to a final
decision of the Patent Office Board of Appeals or Patent Office Board of
Interferences and the applicable foreign equivalent without the consent of
▇▇▇▇▇▇▇, which consent will not be unreasonably withheld taking into
consideration, inter alia, the merits of the action of the Patent and Trademark
Office and the applicable foreign equivalent, priority dates provable by any
interference party (should an interference be involved), and the technological
and commercial importance of the subject matter of the claims of the application
or patent involved expenses shall be borne as provided in Section 4.03.

-7-

ARTICLE V
---------
DISCLOSURE OF AGREEMENT
-----------------------

Section 5.01. Disclosure of Agreement. Except as provided below, neither
--------------------------------------
▇▇▇▇▇▇▇ nor Lilly shall release any information to any third party with respect
to the existence and terms of this Agreement without the prior written consent
of the other party to this Agreement.

This prohibition includes, but is not limited to, press releases,
educational and scientific conferences, promotional materials, governmental
filings, and discussions with lenders, investment bankers, public officials, and
the media.

Section 5.02. Releases Required by Law. If either party determines a
---------------------------------------
release of information is required by law or governmental regulation, it shall
notify the other in writing at least ten (10) days (or such shorter period where
legally required) before the time of the proposed release. The notice shall
include the exact text of the proposed release, the time and manner of the
release, and the basis for such party's belief that disclosure is required.

At the other party's request and before the release, the party desiring to
release information shall consult with the other party on the necessity for the
disclosure and the text of the proposed release. In no event shall a release
include information regarding the existence or terms of this Agreement that is
not required by law or governmental regulation without the consent of the other
party.

Notwithstanding any other terms of this Agreement, either party shall be
permitted and allowed to provide a copy of this Agreement or any terms hereof or
otherwise provide any information with respect to the existence and terms of
this Agreement to appropriate governmental taxing or drug regulatory authorities
requested, without advance written notice or approval of the other party.

ARTICLE VI
----------
CERTAIN UNDERTAKINGS
--------------------

Section 6.01. Lilly Warranties. Lilly hereby warrants that it, to the
-------------------------------
best of its knowledge, is the sole owner of or is duly licensed under the Lilly
Intellectual Property Rights licensed to ▇▇▇▇▇▇▇ hereunder and has a lawful
right to grant the rights and licenses granted to ▇▇▇▇▇▇▇ hereunder.

Section 6.02. ▇▇▇▇▇▇▇ Efforts. ▇▇▇▇▇▇▇ hereby agrees to use its best
-------------------------------
efforts to develop and commercialize Products throughout the Territory. ▇▇▇▇▇▇▇
may abandon development efforts for the Compound at any time if in the
reasonable judgment of ▇▇▇▇▇▇▇ further development efforts are not justified.
If ▇▇▇▇▇▇▇ so abandons development, if shall upon request assign to Lilly or
Lilly's designee all intellectual property, records, data, clinical trial
results and other information relating to the Compound in return for which Lilly
or its designee shall pay to ▇▇▇▇▇▇▇ an amount equal to ▇▇▇▇▇▇▇' total
development costs (including all out of pocket costs

-8-

and reasonable internal costs). Furthermore, upon execution of this Agreement,
▇▇▇▇▇▇▇ shall assume all responsibilities for all adverse event reporting,
annual reporting and any other reporting responsibilities to regulatory agencies
in the Territory.

Section 6.03. Technical Assistance. For a period of one hundred eighty
-----------------------------------
(180) days from the date hereof, Lilly will, through certain designated
personnel, provide ▇▇▇▇▇▇▇ with such technical assistance, information and
advice regarding the use of Lilly Intellectual Property Rights and the Know-How
that may be reasonably necessary in connection with the manufacturing and
testing of the Compound and Product. Lilly, at its expense, also agrees that
such assistance may include one (1) visit to the ▇▇▇▇▇▇▇ facilities (not to
exceed twenty-four (24) hours) located in New Jersey by at least one (1)
qualified member of Lilly's personnel to render on-site technical assistance.
Except for the on-site visit described in this Section 6.03, all costs external
to Lilly and associated with technical assistance shall be borne entirely by
▇▇▇▇▇▇▇. Furthermore, Lilly shall not be required to engage extra personnel or
to provide facilities in connection with providing technical assistance.

ARTICLE VII
-----------
ACCOUNTING
----------

Section 7.01. Sales and Royalty Reports. ▇▇▇▇▇▇▇ shall deliver to Lilly
----------------------------------------
within sixty (60) days after the end of each calendar quarter a
written accounting of ▇▇▇▇▇▇▇' Net Sales and the royalty payment due to Lilly
for such quarter. Such quarterly reports shall be in English and include Net
Sales of products on a country-by-country basis (expressed in United States
dollars or computed under the provisions of Section 7.04 hereof), a sales
forecast for each quarter of the current calendar year, and contain such
information as Lilly may from time to time reasonably request. Annually, October
1, ▇▇▇▇▇▇▇ shall deliver to Lilly a sales forecast, by quarter, for the
subsequent calendar year. All sales and royalty reports shall be directed to ▇▇▇
▇▇▇▇▇ and Company, Attn: Royalty Administration, D.C. ▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇. In the event ▇▇▇▇▇▇▇ makes Sales of
Product(s) to persons other than End Users, ▇▇▇▇▇▇▇ shall require such persons
to provide ▇▇▇▇▇▇▇ with such information as Lilly may reasonably request to
permit Lilly to calculate and verify Net Sales and Royalties due.

Section 7.02. Delivery of Royalty. When ▇▇▇▇▇▇▇ delivers the accounting
----------------------------------
to Lilly, ▇▇▇▇▇▇▇ shall also pay by wire transfer or other method acceptable to
Lilly royalty payments due to Lilly for the preceding calendar quarter. Any
payment not made when due shall bear interest at the United States prime rate on
due date as published in the Wall Street Journal, plus six percent (6%).
-------------------

Section 7.03. Audits. ▇▇▇▇▇▇▇ shall keep accurate records in sufficient
---------------------
detail to enable the amounts due to Lilly hereunder to be determined. During
the term of

-9-

this Agreement and for two (2) years after its termination Lilly shall, not more
than once each year and upon written notice, have the right, at its expense, to
audit the books and records of ▇▇▇▇▇▇▇ has underpaid a royalty amount due under
this Agreement and for two (2) years after its termination Lilly shall, not more
than once each year and upon written notice, have the right, at its expense, to
audit the books and records of ▇▇▇▇▇▇▇ for the purpose of determining the
accuracy of royalty payments. If ▇▇▇▇▇▇▇ has underpaid a royalty amount due
under this Agreement by more than five percent (5%), ▇▇▇▇▇▇▇ shall, in addition
to paying any royalties due, also reimburse Lilly for the cost of such audit.

Section 7.04. Exchange Rates and Currency Translation. All payments to be
-----------------------------------------------------
made by ▇▇▇▇▇▇▇ to ▇▇▇▇▇ under this Agreement shall be made and reported in
United States dollars. The rate of exchange to be used in computing the amount
of Net Sales and the United States dollars due Lilly shall be calculated using
▇▇▇▇▇▇▇' then current standard exchange rate methodology, which methodology is
used by ▇▇▇▇▇▇▇ in the translation of its foreign currency operating results for
external reporting, is consistent with United States generally accepted
accounting principles and generally reviewed and approved by ▇▇▇▇▇▇▇'
independent certified public accountants.

Section 7.05. Withholding Taxes. ▇▇▇▇▇▇▇ shall have no liability for any
--------------------------------
income taxes levied against Lilly on account of royalties paid hereunder. If a
laws or regulations require that any such taxes be withheld by ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇
shall deduct such taxes from the payment due Lilly, pay the taxes so withheld to
the proper taxing authority, and send proof of payment to Lilly annually within
ninety (90) days of the first day of the year following such payment. If Lilly
desires to obtain a refund of any taxes so withheld and paid to a taxing
authority, ▇▇▇▇▇▇▇ shall cooperate in the pursuit of such refund.

ARTICLE VIII
------------
TERM AND TERMINATION
--------------------

Section 8.01. Term. This Agreement shall become effective on the date
-------------------
hereof, and shall remain in effect until the later of either: (i) the life of
the last to expire of the patents encompassed in the Lilly Intellectual
Property, or (ii) fifteen (15) years from the date hereof. Upon termination of
this Agreement set forth in this Section 8.01, the licenses granted to ▇▇▇▇▇▇▇
hereunder shall be deemed to be paid up in full.

Section 8.02. Termination by Default. If either party is in default of
-------------------------------------
any of its material obligations under this Agreement, or fails to remedy such a
default within sixty (60) days after the other party sends written notice
detailing the substance of the default to the defaulting party, the injured
party may terminate this Agreement by written notice. In the event Lilly elects
to terminate this Agreement by reason of any default by ▇▇▇▇▇▇▇, the licenses
granted hereunder shall terminate.

-10-

Section 8.03. Residual Obligation Upon Termination. Termination of this
---------------------------------------------------
Agreement for any reason whatsoever will not release or discharge Lilly or
▇▇▇▇▇▇▇ from the performance of any obligation or the payment of any debt which
may have previously accrued and remains to be performed, paid or discharged, at
the date of such termination. However, upon termination no further obligations
under this Agreement shall be incurred by Lilly or ▇▇▇▇▇▇▇.

ARTICLE IX
----------
MISCELLANEOUS PROVISIONS
------------------------

Section 9.01. Amendment. This Agreement may not be amended, supplemented
------------------------
or otherwise modified except by an instrument in writing signed by an authorized
representative of both parties.

Section 9.02. Entire Agreement. This Agreement constitutes the complete
-------------------------------
and definitive agreement of the parties on the subject matter hereof and
supersedes, cancels and annuls all prior or subsequent agreements,
understandings and undertakings relating to the subject matter hereof including,
but without limiting the generality of the foregoing, any documents used by the
parties in making or accepting any offer. There are no verbal agreements,
warranties, representations or understandings affecting this Agreement, and all
previous or other negotiations, representations and understandings between Lilly
and ▇▇▇▇▇▇▇ are merged herein.

Section 9.03. Severability. Each party agrees that, should any provision
---------------------------
of this Agreement be determined by a court of competent jurisdiction to violate
or contravene any applicable law or policy, such provision will be severed or
modified by the court to the extent necessary to comply with the applicable law
or policy, and such modified provision and the remainder of the provisions
hereof will continue in full force and effect. The parties specifically agree
that nothing in this Agreement is intended to require either party to take, or
not take, any action which would constitute a violation of any applicable law or
regulation, including but not limited to those regarding trade.

Section 9.04. Notices. Any notice required or permitted to be given under
----------------------
this Agreement shall be in writing and shall be deemed to have been sufficiently
given for all purposes if mailed by first class certified or registered mail,
postage prepaid, or sent by national overnight delivery service, or by
acknowledged facsimile. Unless otherwise specified in writing, the mailing
addresses of the parties shall be as follows:

-11-

For ▇▇▇▇▇▇▇:

▇▇▇▇▇▇▇ Laboratories Inc.
▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
Attention: ▇.▇. ▇▇▇▇▇▇, Vice President

For Lilly:

▇▇▇ ▇▇▇▇▇ and Company
Lilly ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: General Counsel

Section 9.05. Governing Law. This Agreement shall be governed by, and
----------------------------
construed in accordance with, the laws of Indiana, excluding any choice of law
rules which may direct the application of the law of any other jurisdiction.

Section 9.06. Assignment. Except as expressly provided herein, neither
-------------------------
party may assign its rights and obligations under this Agreement except to an
Affiliate without prior written consent of the other, except a party may make
such an assignment without the other party's consent in connection with any
merger or sale of all or substantially all of its assets to which this Agreement
relates. This Agreement shall be binding upon the inure to the benefit of the
successors permitted assignees of the parties hereto.

Section 9.7. Consents Not Unreasonably Withheld. Whenever provision is
------------------------------------------------
made in this Agreement for either party to secure the consent or approval of the
other, that consent or approval shall not unreasonably be withheld, and whenever
in this Agreement provisions are made for one party to object to or disapprove a
matter, such objection or disapproval shall not unreasonably be exercised.

Section 9.8. No Strict Construction. This Agreement has been prepared
------------------------------------
jointly and shall not be strictly construed against either party.

Section 9.9. Captions. The captions or headings of the Sections or other
----------------------
subdivisions hereof are inserted only as a matter of convenience or for
reference and shall have no effect on the meaning of the provisions hereof.

-12-

or lockout, act of God, war, fire, flood, embargo, act of any governmental
authority, riot, or any other unforeseeable cause or causes beyond the
reasonable control and without the fault or negligence of the party so affected.
The party so affected shall give prompt notice to the other party of such cause,
and shall take whatever reasonable steps are appropriate in the party's
discretion to relieve the effect of such cause as rapidly as possible.

Section 9.11. Currency. All references to "$" or "dollars" in this
----------------------
agreement shall refer to United States dollars.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement by
their respective officers thereunto duly authorized.

▇▇▇▇▇▇▇ LABORATORIES INC. ▇▇▇ LILLY AND COMPANY

By: /s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
---------------------- ------------------------
Title: Vice President Title: Executive Vice President
---------------------- and Chief Financial Officer

In order to induce Lilly to execute this Agreement, ▇▇▇▇▇▇▇ Pharmaceutical
Corporation, the parent company of ▇▇▇▇▇▇▇ Laboratories Inc., hereby
unconditionally guarantees the due payment and performance of all obligations of
▇▇▇▇▇▇▇ Laboratories Inc. contained in this Agreement.

By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
------------------------
Title: Vice President

APPENDIX A

Know-How shall mean all written information in the possession of Lilly
regarding the Compound of the types listed below reasonably useful to ▇▇▇▇▇▇▇ in
developing and manufacturing the compound. Lilly shall use its reasonable
efforts to locate and furnish to ▇▇▇▇▇▇▇ all material documents representing
Know-How. ▇▇▇▇▇▇▇ acknowledges that certain records may have been lost or
destroyed or otherwise be unavailable. Provided that Lilly has used its
reasonable efforts to locate such documents, Lilly shall have no further
obligation to ▇▇▇▇▇▇▇ with respect to such documents.

Marketing . Market research on GI markets prepared with
respect to the Compound.

. Initial forecasts of market potential for the Compound

Toxicology . Written summary reports for the Compound

Project Management . For the Compound for the 2 years prior to
Status Reports discontinuation of Lilly's development effort.

Regulatory . CTX for the Compound

. All other material regulatory documents relating to the
Compound, including any and all clinical data

APPENDIX B

LY213829 (TAZOFELONE) PATENT SUMMARY
------------------------------------

Lilly Docket No. Subject Matter
---------------- --------------

X-6428 Compound (racemate)

X-7812 Method of Treating IBD:
Process for Preparing Enantiomers

X-8830 Process for Preparing Enantiomers

P-9667 Crystal Form of Racemate

EXHIBIT 10.81

LICENSE AGREEMENT
[LY246736]

RECITALS
--------

1. Lilly and ▇▇▇▇▇▇▇ are in the business of discovering, developing and
marketing pharmaceutical products.

2. Lilly has discovered a compound internally designated as LY246736 (as
defined in Section 1.02 below, the "Compound") which may be useful in the
treatment of functional gastrointestinal disorders and other indications. Lilly
has previously engaged in certain research and development efforts with respect
to the Compound, but has concluded that future development efforts could best be
conducted by a company with a focus on gastrointestinal products.

AGREEMENT
---------

In consideration of the Recitals and the mutual covenants and agreements
set forth below, the parties agree as follows:

ARTICLE I
---------
DEFINITIONS
-----------

When used in this Agreement, each of the following terms shall have the
meanings set forth below.

Section 1.02. "Compound" means (+)-[[2(S)-[[4(R)-(3-hydroxyphenyl)-3(R),4-
------------
dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]amino]-acetic acid and all
pharmaceutically acceptable salts and solvates thereof.

-2-

Section 1.03. "End User" means a wholesaler, distributor, pharmacy,
------------
hospital, health care organization or patient.

Section 1.06. "Net Sales" means with respect to a Product, the gross
------------
amount invoiced by ▇▇▇▇▇▇▇, or any sublicensee, to an End User less the
following deductions:

1. Trade, quantity and cash discounts actually given or allowed;

2. Rebates, allowances, Medicaid and Medicaid reimbursements, chargebacks
and similar deductions;

3. Any tax imposed on the sale, delivery or use of the product, and

4. Allowances or credits for returned goods or rejections of any Product
which in unsalable.

Section 1.07. "Product" means any pharmaceutical composition for use as a
------------
therapeutic or diagnostic product that incorporates the Compound.

Section 1.08. "Territory" means the entire world.
------------

ARTICLE II
----------
LICENSE
-------

-3-

patent claims necessary to provide ▇▇▇▇▇▇▇ with the ability to make, have made,
use or sell Product within the Territory and shall, further, be limited solely
to the right to make, have made, use or sell Product within the Territory. Such
license shall include the right of ▇▇▇▇▇▇▇ to sublicense, consistent with the
terms of this Agreement. All terms and provisions of this Agreement shall apply
to each sublicense to the same extent as they apply to ▇▇▇▇▇▇▇, and ▇▇▇▇▇▇▇
shall guarantee performance by its sublicensee of all obligations imposed under
the terms of this Agreement

ARTICLE III
-----------
PAYMENTS AND ROYALTIES
----------------------

Section 3.01. Signing and Milestone Payments.
---------------------------------------------

(a) As consideration for the licenses granted hereunder, ▇▇▇▇▇▇▇ shall pay
Lilly by wire transfer to an account designated by Lilly the following
amounts at the following times:

(i) Upon execution of this Agreement $500,000

(v) Upon acceptance of the first New $500,000
Drug Application or similar filing in
the United States, Canada, Japan or
the European Community that seeks
permission to market a Product:

(b) All payments described above shall be made within thirty (30) days of
the relevant event, except for the payment described in (a)(i), which shall
be made upon signing of this Agreement. Any payment not made when due
shall bear interest at the United States prime rate on the due date as
published in the Wall Street Journal, plus six percent (6%).
-------------------

Section 3.02. Royalty. As additional consideration for the licenses
---------------------
granted hereunder, ▇▇▇▇▇▇▇ shall pay to Lilly a royalty equal to 7% of Net Sales
of Product in the Territory. Royalties shall be reported and paid quarterly in
accordance with Article VII of this Agreement.

ARTICLE IV
----------
PROSECUTION AND INFRINGEMENT OF INTELLECTUAL
--------------------------------------------
PROPERTY RIGHTS
---------------

Section 4.01. Patent Term Extensions and Supplementary Protection
------------------------------------------------------------------
Certificates. Lilly upon request of ▇▇▇▇▇▇▇ shall apply for (and ▇▇▇▇▇ ▇▇▇▇▇▇▇ a
------------
license under) patent term extensions, Supplementary Protection Certificates or
functional equivalents thereof, in any jurisdiction within the Territory where
such items are permissible, for any Lilly Intellectual

-4-

Property Rights licensed to ▇▇▇▇▇▇▇ hereunder. ▇▇▇▇▇▇▇ will provide Lilly with
all material and information as may be necessary to obtain any of the aforesaid
rights.

Section 4.02. Prosecution and Maintenance of Licensed Patents.
--------------------------------------------------------------

(a) Appendix B attached hereto identifies all pending applications and
patents worldwide which are encompassed in the Lilly Intellectual Property
Rights.

(b) Lilly shall prosecute any pending applications of which it is the owner
that are encompassed in the Lilly Intellectual Property Rights and maintain
any patents that have issued or will issue thereon in full force and effect
for the term of such patent. Should, during the course of prosecution of
any pending claims, an official action rejecting the claims require that an
amendment be made or action be taken which would limit or substantially
change the scope of any license hereunder, Lilly will timely inform ▇▇▇▇▇▇▇
in writing. Lilly shall consult ▇▇▇▇▇▇▇ before responding to any such
official action, and allow ▇▇▇▇▇▇▇ to assist in the prosecution of such
claims or, at Lilly's option, allow ▇▇▇▇▇▇▇ the opportunity at its time and
expense to prosecute such claims to ▇▇▇▇▇▇▇ satisfaction.

Section 4.03. Costs of Prosecution and Maintenance of Patents. Lilly
--------------------------------------------------------------
shall bear all costs incurred in filing, prosecuting and maintaining all patents
and patent applications encompassed within the Intellectual Property Rights,
provided, however, that ▇▇▇▇▇▇▇ shall pay one-half (1/2) of all reasonable
external expenses incurred by Lilly while prosecuting and maintaining such
patents and patent applications. External expenses will include patent office
fees and taxes in connection with the prosecution and maintenance of any patent
or patent application and the fees of any patent attorneys or agents, external
of Lilly, in connection with the ex parte prosection and maintenance thereof.
-- -----
The allocation of such expenses will occur on a annual basis at the end of the
last quarter of each calendar year, at which time Lilly will provide ▇▇▇▇▇▇▇
with an itemized list of external expenses denominated in United States dollars
incurred during the previous annual period. ▇▇▇▇▇▇▇ will then reimburse Lilly's
expenses within sixty (60) days of the date of receipt of this itemized list.
Notwithstanding the foregoing, Lilly may, at its sole discretion, choose not to
prosecute or cease to maintain a patent or patent application in any country as
it so desires and to the extent that Lilly chooses not to prosecute or ceases to
maintain such patent or patent application Lilly shall not be responsible for
any patent costs associated with prosecuting and/or maintaining the patent or
patent application in such country. If ▇▇▇▇▇▇▇ desires to prosecute or maintain
such patent or patent application ▇▇▇▇▇▇▇ may do so at its own expense; however,
under these circumstances, Lilly would ▇▇▇▇▇ ▇▇▇▇▇▇▇ all of its patent rights
associated with such patent in such country. Similarly, upon written notice to
Lilly, ▇▇▇▇▇▇▇ may elect not to share in the prosecution or maintenance costs as
described in this Section 4.03 related to a patent or patent application in a
particular country; however, upon such election any rights that ▇▇▇▇▇▇▇ has in
such patent in such country would be granted to Lilly.

-5-

Section 4.04. Option by ▇▇▇▇▇▇▇ to Discontinue License. ▇▇▇▇▇▇▇, at its
-------------------------------------------------------
option, may elect to discontinue the license granted and surrender all rights
hereunder as to any patent on a country-by-country basis. Such election must be
made by thirty (30) days written notice by simultaneous facsimile transmission
and certified mailing, and, with respect to the surrender of ▇▇▇▇▇▇▇' rights,
will be effective as of the date of mailing. In the event such an election is
made, Lilly's obligations under Sections 4.01 and 4.02 and ▇▇▇▇▇▇▇' obligations
under Section 4.03 will terminate thirty (30) days from the date of mailing with
respect to the specific patent on which the election is made.

Section 4.05. Infringement. Each party shall give prompt notice to the
---------------------------
other of any infringement, potential infringement or suspected infringement of
Lilly Intellectual Property Rights that may come to such party's attention.
Promptly thereafter, the parties shall consult and cooperate fully to determine
a course of action, including, but not limited to, the commencement of legal
action by one or both parties, to cause such infringement, potential
infringement or suspected infringement to be terminated. Each party, at its
option, may elect to participate in or commence such a legal action. In the
event of a joint action in which both parties agree to participate, the parties
will share in the costs and the recovery of the agreed upon course of action in
a manner to be agreed upon. Failing agreement on a course of action to ▇▇▇▇▇
infringement, potential infringement or suspected infringement within sixty (60)
days of the time of such infringement, potential infringement or suspected
infringement becomes known to both parties, either party shall have the right,
at its own expense, to initiate and prosecute an action against the infringer
and shall retain whatever damages are recovered. In the event ▇▇▇▇▇▇▇ is unable
to initiate and prosecute such action solely in its own name, Lilly will execute
(and cause its Affiliates to execute) all documents necessary for ▇▇▇▇▇▇▇ to
initiate and prosecute such action. Neither party will enter into any
settlement of any action referred to in this Section without the other party's
prior consent, which consent shall not be unreasonably withheld.

-6-

ARTICLE V
---------
DISCLOSURE OF AGREEMENT
-----------------------

ARTICLE VI
----------
CERTAIN UNDERTAKINGS
--------------------

Section 6.02. ▇▇▇▇▇▇▇ Efforts. ▇▇▇▇▇▇▇ hereby agrees to use its best
-----------------------------
efforts to develop and commercialize Products throughout the Territory. ▇▇▇▇▇▇▇
may abandon development efforts for the Compound at any time if in the
reasonable judgment of ▇▇▇▇▇▇▇ further development efforts are not justified.
If ▇▇▇▇▇▇▇ so abandons development, it shall upon request assign to Lilly or
Lilly's designee all intellectual property, records, data, clinical trial
results and other information relating to the Compound in return for which Lilly
or its

-7-

designee shall pay to ▇▇▇▇▇▇▇ an amount equal to ▇▇▇▇▇▇▇' total development
costs (including all out of pocket costs and reasonable internal costs). ▇▇▇▇▇▇▇
shall comply with all responsibilities for all adverse event reporting, annual
reporting and any other reporting responsibilities to regulatory agencies in the
Territory.

ARTICLE VII
-----------
ACCOUNTING
----------

Section 7.01. Sales and Royalty Reports. ▇▇▇▇▇▇▇ shall deliver to Lilly
----------------------------------------
within sixty (60) days after the end of each calendar quarter a written
accounting of ▇▇▇▇▇▇▇' Net Sales and the royalty payment due to Lilly for such
quarter. Such quarterly reports shall be in English and include the Net Sales
of products on a country-by-country basis (expressed in United States dollars or
computed under the provisions of Section 7.04 hereof), a sales forecast for each
quarter of the current calendar year, and contain such other information as
Lilly may from time to time reasonably request. Annually, by October 1, ▇▇▇▇▇▇▇
shall deliver to Lilly a sales forecast, by quarter, for the subsequent calendar
year. All sales and royalty reports shall be directed to ▇▇▇ ▇▇▇▇▇ and Company,
Attn: Royalty Administration, D.C. ▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇,
▇▇▇▇▇▇▇ ▇▇▇▇▇. In the event ▇▇▇▇▇▇▇ makes Sales of Product(s) to persons other
than End Users, ▇▇▇▇▇▇▇ shall require such persons to provide ▇▇▇▇▇▇▇ with such
information as Lilly may reasonably request to permit Lilly to calculate and
verify Net Sales and Royalties due.

-8-

▇▇▇▇▇▇▇ for the purpose of determining the accuracy of royalty payments. If
▇▇▇▇▇▇▇ has underpaid a royalty amount due under this Agreement by more than
five percent (5%), ▇▇▇▇▇▇▇ shall, in addition to paying any royalties due, also
reimburse Lilly for the cost of such audit.

Section 7.04. Exchange Rates and Currency Translation. All payments to be
------------------------------------------------------
made by ▇▇▇▇▇▇▇ to ▇▇▇▇▇ under this Agreement shall be made and reported in
United States dollars. The rate of exchange to be used in computing the amount
of Net Sales and the United States dollars due Lilly shall be calculated using
▇▇▇▇▇▇▇' then current standard exchange rate methodology, which methodology is
used by ▇▇▇▇▇▇▇ in the translation of its foreign currency operating results for
external reporting, is consistent with United States generally accepted
accounting principles and generally reviewed and approved by ▇▇▇▇▇▇▇'
independent certified public accountants.

Section 7.05. Withholding Taxes. ▇▇▇▇▇▇▇ shall have no liability for any
--------------------------------
income taxes levied against Lilly on account of royalties paid hereunder. If
laws or regulations require that any such taxes be withheld by ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇
shall deduct such taxes from the payment due Lilly, pay the taxes to withheld to
the proper taxing authority, and send proof of payment to Lilly annually within
ninety (90) days of the first day of the year following such payment. If Lilly
desires to obtain a refund of any taxes so withheld and paid to a taxing
authority, ▇▇▇▇▇▇▇ shall cooperate in the pursuit of such refund.

ARTICLE VIII
------------
TERM AND TERMINATION
--------------------

Section 8.01. Term. This Agreement shall become effective on the date
-------------------
hereof, and shall remain in effect until the later of either: (i) the life of
the last to expire of the patents encompassed in the Lilly Intellectual
Property, or (ii) fifteen (15) years from the date hereof. Upon termination of
this Agreement as set forth in this Section 8.01, the licenses granted to
▇▇▇▇▇▇▇ hereunder shall be deemed to be paid up in full.

-9-

ARTICLE IX
----------
MISCELLANEOUS PROVISIONS
------------------------

Section 9.01. Amendment. This Agreement may not be amended, supplemented
-----------------------
or otherwise modified except by an instrument in writing signed by an authorized
representative of both parties.

For ▇▇▇▇▇▇▇:

For Lilly:

▇▇▇ ▇▇▇▇▇ and Company
Lilly ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: General Counsel

-10-

Section 9.06. Assignment. Except as expressly provided herein, neither
-------------------------
party may assign its rights and obligations under this Agreement except to an
Affiliate without the prior written consent of the other, except a party may
make such an assignment without the other party's consent in connection with any
merger or sale of all or substantially all of its assets to which this Agreement
relates. This Agreement shall be binding upon and inure to the benefit of the
successors and permitted assignees of the parties hereto.

Section 9.8. No Strict Construction. This Agreement has been prepared
------------------------------------
jointly and shall not be strictly construed against either party.

Section 9.10. Force Majeure. Any delay or failure in the performance of
----------------------------
any of the duties or obligations of any party hereto caused by an event outside
the affected party's reasonable control shall not be considered a breach of this
Agreement, and the time required for such party's performance shall be extended
for a period equal to the period of such delay. Such events shall include,
without limitation, any labor strike or lockout, act of God, war, fire, flood,
embargo, act of any governmental authority, riot, or any other unforeseeable
cause or causes beyond the reasonable control and without the fault or
negligence of the party so affected. The party so affected shall give prompt
notice to the other party of such cause, and shall take whatever reasonable
steps are appropriate in the party's discretion to relieve the effect of such
cause as rapidly as possible.

Section 9.11. Currency. All references to "$" or "dollars" in this
-----------------------
agreement shall refer to United States dollars.

-11-

IN WITNESS WHEREOF, the parties hereto have executed this Agreement by
their respective officers thereunto duly authorized.

▇▇▇▇▇▇▇ LABORATORIES INC. ▇▇▇ LILLY AND COMPANY

By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
----------------------- ------------------------------
Title: President Title: Executive Vice President
and Chief Financial Officer

By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
-----------------------
Title: Vice President

APPENDIX A

Marketing . Market research on GI markets prepared
with respect to the Compound

. Initial forecasts of market potential for the
Compound

Toxicology . Written summary reports for the
Compound

Project Management . For the Compound for the 2 years prior
Status Reports to discontinuation of Lilly's development
effort

Regulatory . Material regulatory documents relating to
the Compound, if any

Appendix B

Patent Status
-------------

LY246736
--------

X-8244 Compound, Method, Formulation
X-8847 Intermediate, Process, Salt, Dihydrate

Exhibit 10.81

LICENSE AGREEMENT
[LY353433]

This License Agreement ("Agreement") is made as of the 5th day of November,
1996 by and between ▇▇▇ ▇▇▇▇▇ and Company, an Indiana corporation ("Lily") and
▇▇▇▇▇▇▇ Laboratories Inc., a New Jersey corporation ("▇▇▇▇▇▇▇").

RECITALS
--------

1. Lilly and ▇▇▇▇▇▇▇ are in the business of discovering, developing and
marketing pharmaceutical products.

2. Lilly has discovered a compound internally designated as LY353433 (as
defined in Section 1.02 below, the "Compound") which may be useful in the
treatment of functional gastrointestinal disorders and other indications. Lilly
has previously engaged in certain research and development efforts including
limited clinical trials with respect to the Compound, but has concluded that
future development efforts could best be conducted by a company with a focus on
gastrointestinal products.

AGREEMENT
---------

In consideration of the Recitals and the mutual covenants and agreements
set forth below, the parties agree as follows:

ARTICLE 1
---------
DEFINITIONS
-----------

When used in this Agreement, each of the following terms shall have the
meanings set forth below.

Section 1.02. "Compound" means 1-(1-methylethyl)-N-[2-[4-
------------
[(tricyclo[3.3.1.1 (3,7)]-dec-1-ylcarbonyl)amino]-1-piperidinyl]ethyl]-1H-
indazole-3-carboxamide and all pharmaceutically acceptable salts and solvates
thereof.

-2-

Section 1.03. "End User" means a wholesaler, distributor, pharmacy,
------------
hospital, health care organization or patient.

Section 1.05. "Lily Intellectual Property Rights" means all patent rights,
------------
trade secret rights, and Know-How rights owned, licensed or otherwise controlled
by Lilly as of the date hereof which encompass Compound and Product or are
useful in preparing Compound and are effective in the Territory, including all
divisions, continuations, continuations-in-part, reissuances, reexaminations,
extensions, Supplementary Protection Certificates, and any similar intellectual
property rights, and all counterparts thereof in the Territory. A list of all
patent rights owned, licensed or otherwise controlled by Lilly as of the date
hereof and which are encompassed hereunder is attached as Appendix B.

Section 1.06. "Net Sales" means with respect to a Product, the gross
------------
amount invoiced by ▇▇▇▇▇▇▇, or any sublicensee, to an End User less the
following deductions:

1. Trade, quantity and cash discounts actually given or allowed;

2. Rebates, allowances, Medicaid and Medicare reimbursements, chargebacks
and similar deductions;

3. Any tax imposed on the sale, delivery or use of the product; and

4. Allowances or credits for returned goods or rejections of any Product
which is unsalable.

Section 1.07. "Product" means any pharmaceutical composition for use as a
------------
therapeutic or diagnostic product that incorporates the Compound.

Section 1.08. "Territory" means the entire world.
------------

ARTICLE II
----------
LICENSE
-------

-3-

ARTICLE III
-----------
PAYMENTS AND ROYALTIES
----------------------

Section 3.01. Signing and Milestone Payments.
---------------------------------------------

(a) As consideration for the licenses granted hereunder, ▇▇▇▇▇▇▇ shall pay
Lilly by wire transfer to an account designated by Lilly the following
amounts at the following times:

(i) Upon execution of this Agreement $500,000

(ii) Upon acceptance of the first New $500,000
Drug Application or similar filing the
United States, Canada, Japan or the
the European Community that seeks
permission to market a Product:

(b) All payments described above shall be made within thirty (30) days of
the relevant event, except for the payment described in (a)(i), which shall
be made upon signing of this Agreement. Any payment not made when due
shall bear interest at the United States prime rate on the due date as
published in the Wall Street Journal, plus six percent (6%).
-------------------

Section 3.02. Royalty. As additional consideration for the licenses
----------------------
granted hereunder, ▇▇▇▇▇▇▇ shall pay to Lilly a royalty equal to 7% of Net Sales
of Product in the Territory. Royalties shall be reported and paid quarterly in
accordance with Article VII of this Agreement.

ARTICLE IV
----------
PROSECUTION AND INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS
------------------------------------------------------------

-4-

Property Rights licensed to ▇▇▇▇▇▇▇ hereunder. ▇▇▇▇▇▇▇ will provide Lilly with
all material and information as may be necessary to obtain any of the aforesaid
rights.

Section 4.02. Prosecution and Maintenance of Licensed Patents.
--------------------------------------------------------------

(a) Appendix B attached hereto identifies all pending applications and
patents worldwide which are encompassed in the Lilly Intellectual
Property Rights.

(b) Lilly shall prosecute any pending applications of which it is the owner
that are encompassed in the Lilly Intellectual Property Rights and
maintain any patents that have issued or will issue thereon in full
force and effect for the term of such patent. Should, during the course
of prosecution of any pending claims, an official action rejecting the
claims require that an amendment be made or action be taken which would
limit or substantially change the scope of any license hereunder, Lilly
will timely inform ▇▇▇▇▇▇▇ in writing. Lilly shall consult ▇▇▇▇▇▇▇
before responding to any such official action, and allow ▇▇▇▇▇▇▇ to
assist in the prosecution of such claims or, at Lilly's option, allow
▇▇▇▇▇▇▇ the opportunity at its time and expense to prosecute such
claims to ▇▇▇▇▇▇▇ satisfaction.

Section 4.03. Costs of Prosecution and Maintenance of Patents. Lilly
--------------------------------------------------------------
shall bear all costs incurred in filing, prosecuting and maintaining all patents
and patent applications encompassed within the Intellectual Property Rights,
provided, however, that ▇▇▇▇▇▇▇ shall pay one-half (1/2) of all reasonable
external expenses incurred by Lilly while prosecuting and maintaining such
patents and patent applications. External expenses will include patent office
fees and taxes in connection with the prosecution and maintenance of any patent
or patent application and the fees of any patent attorneys or agents, external
of Lilly, in connection with the ex parte prosecution and maintenance thereof.
-- -----
The allocation of such expenses will occur on an annual basis at the end of the
last quarter of each calendar year, at which time Lilly will provide ▇▇▇▇▇▇▇
with an itemized list of external expenses denominated in United States dollars
incurred during the previous annual period. ▇▇▇▇▇▇▇ will then reimburse Lilly's
expenses within sixty (60) days of the date of receipt of this itemized list.
Notwithstanding the foregoing, Lilly may, at its sole discretion, choose not to
prosecute or cease to maintain a patent or patent application in any country as
it so desires and to the extent that Lilly chooses not to prosecute or ceases to
maintain such patent or patent application Lilly shall not be responsible for
any patent costs associated with prosecuting and/or maintaining the patent or
patent application in such country. If ▇▇▇▇▇▇▇ desires to prosecute or maintain
such patent or patent application ▇▇▇▇▇▇▇ may do so at its own expense; however,
under these circumstances, Lilly would ▇▇▇▇▇ ▇▇▇▇▇▇▇ all of its patent rights
associated with such patent in such country. Similarly, upon written notice to
Lilly, ▇▇▇▇▇▇▇ may elect not to share in the prosecution or maintenance costs as
described in this Section 4.03 related to a patent or patent application in a
particular country; however, upon such election any rights that ▇▇▇▇▇▇▇ has in
such patent in such country would be granted to Lilly.

-5-

Section 4.04. Option by ▇▇▇▇▇▇▇ to Discontinue License. ▇▇▇▇▇▇▇, at its
-------------------------------------------------------
option, may elect to discontinue the license granted and surrender all rights
hereunder as to any patent on a country-by-country basis. Such election must be
made by thirty (30) days written notice by simultaneous facsimile transmission
and certified mailing, and, with respect to the surrender of ▇▇▇▇▇▇▇' rights,
will be effective as of the date of mailing. In the event such an election is
made, Lilly's obligations under Section 4.01 and 4.02 and ▇▇▇▇▇▇▇' obligations
under Section 4.03 will terminate thirty (30) days from the date of mailing with
respect to the specific patent on which the election is made.

Section 4.05. Infringement. Each party shall give prompt notice to the
---------------------------
other of any infringement, potential infringement or suspected infringement of
Lilly Intellectual Property Rights that may come to such party's attention.
Promptly thereafter, the parties shall consult and cooperate fully to determine
a course of action, including, but not limited to, the commencement of legal
action by one or both parties, to cause such infringement, potential
infringement, or suspected infringement to be terminated. Each party, at its
option, may elect to participate in or commence such a legal action. In the
event of a joint action in which both parties agree to participate, the parties
will share in the costs and the recovery of the agreed upon course of action in
a manner to be agreed upon. Failing agreement on a course of action to ▇▇▇▇▇
infringement, potential infringement or suspected infringement within sixty (60)
days of the time such infringement, potential infringement or suspected
infringement becomes known to both parties, either party shall have the right,
at its own expense, to initiate and prosecute an action against the infringer
and shall retain whatever damages are recovered. In the event ▇▇▇▇▇▇▇ is unable
to initiate and prosecute such action solely in its own name, Lilly will execute
(and cause its Affiliates to execute) all documents necessary for ▇▇▇▇▇▇▇ to
initiate and prosecute such action. Neither party will enter into any
settlement of any action referred to in this Section without the other party's
prior consent, which consent shall not be unreasonably withheld.

-6-

ARTICLE V
---------
DISCLOSURE OF AGREEMENT
-----------------------

ARTICLE VI
----------
CERTAIN UNDERTAKINGS
--------------------

Section 6.02. ▇▇▇▇▇▇▇ Efforts. ▇▇▇▇▇▇▇ hereby agrees to use its best
------------------------------
efforts to develop and commercialize Products throughout the Territory. ▇▇▇▇▇▇▇
may abandon development efforts for the Compound at any time if in the
reasonable judgment of ▇▇▇▇▇▇▇ further development efforts are not justified.
If ▇▇▇▇▇▇▇ so abandons development, it shall upon request assign to Lilly or
Lilly's designee all intellectual property, records, data, clinical trial
results and other information relating to the Compound in return for which Lilly
or its designee shall pay to ▇▇▇▇▇▇▇ an amount equal to ▇▇▇▇▇▇▇' total
development costs (including all out of pocket costs and reasonable internal
costs). Furthermore, upon execution of this Agreement, ▇▇▇▇▇▇▇ shall comply
with all responsibilities for all adverse

-7-

event reporting, annual reporting and any other reporting responsibilities to
regulatory agencies in the Territory.

ARTICLE VII
-----------
ACCOUNTING
----------

Section 7.01. Sales and Royalty Reports. ▇▇▇▇▇▇▇ shall deliver to Lilly
---------------------------------------
within sixty (60) days after the end of each calendar quarter a written
accounting of ▇▇▇▇▇▇▇' Net Sales and the royalty payment due to Lilly for such
quarter. Such quarterly reports shall be in English and include the Net Sales
of products on a country-by-country basis (expressed in United States dollars or
computed under the provisions of Section 7.04 hereof), a sales forecast for each
quarter of the current calendar year, and contain such other information as
Lilly may from time to time reasonably request. Annually, by October 1, ▇▇▇▇▇▇▇
shall deliver to Lilly a sales forecast, by quarter, for the subsequent calendar
year. All sales and royalty reports shall be directed to ▇▇▇ ▇▇▇▇▇ and Company,
Attn: Royalty Administration, D.C. ▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇,
▇▇▇▇▇▇▇ ▇▇▇▇▇. In the event ▇▇▇▇▇▇▇ makes Sales of Product(s) to persons other
than End Users, ▇▇▇▇▇▇▇ shall require such persons to provide ▇▇▇▇▇▇▇ with such
information as Lilly may reasonably request to permit Lilly to calculate and
verify Net Sales and Royalties due.

Section 7.03. Audits. ▇▇▇▇▇▇▇ shall keep accurate records in sufficient
---------------------
form to enable the amounts due to Lilly hereunder to be determined. during the
term of this Agreement and for two (2) years after its termination, shall not
more than once each year and upon written notice, have at its expense, to audit
the books and records of ▇▇▇▇▇▇▇ for the purpose of determining the accuracy of
royalty payments. If ▇▇▇▇▇▇▇ has underpaid a royalty amount due under this
Agreement by more than five percent (5%),

-8-

▇▇▇▇▇▇▇ shall, in addition to paying any royalties due, also reimburse Lilly for
cost of such audit.

Section 7.04. Exchange Rates and Currency Translation. All payments to be
------------------------------------------------------
made by ▇▇▇▇▇▇▇ to ▇▇▇▇▇ under this Agreement shall be made and reported in
United States dollars. The rate of exchange to be used in computing the amount
of Net Sales and the United States dollars due Lilly will be calculated using
▇▇▇▇▇▇▇' then current standard exchange rate methodology, which methodology is
used by ▇▇▇▇▇▇▇ in the translation of its foreign currency operating results for
external reporting, is consistent with United States generally accepted
accounting principles and generally reviewed and approved by ▇▇▇▇▇▇▇'
independent certified public accountants.

Section 7.05. Withholding Taxes. ▇▇▇▇▇▇▇ shall have no liability for
--------------------------------
any income taxes levied against Lilly on account of royalties paid hereunder.
If any law regulations require that any such taxes be withheld by ▇▇▇▇▇▇▇,
▇▇▇▇▇▇▇ shall deduct such taxes from the payment due Lilly, pay the taxes so
withheld to the proper taxing authority, and send proof of payment to Lilly
annually within ninety (90) days of the first day of the year following such
payment. If Lilly desires to obtain a refund of any taxes so withheld and paid
from a taxing authority, ▇▇▇▇▇▇▇ shall cooperate in the pursuit of such refund.

ARTICLE VIII
------------
TERM AND TERMINATION
--------------------

Section 8.01. Term. This Agreement shall become effective on the date
-------------------
hereof, and shall remain in effect until the later of either: (i) the life of
the last to expire of the patents encompassed in the Lilly Intellectual
Property, or (ii) fifteen (15) years from the date hereof. Upon termination of
this Agreement as set forth in this Section 8.01, the licenses granted to
▇▇▇▇▇▇▇ hereunder shall be deemed to be paid up in full.

Section 8.02. Termination by Default. If either party is in default of
-------------------------------------
its material obligations under this Agreement, or fails to remedy such default
within sixty (60) days after the other party sends written notice detailing the
substance of the default to the defaulting party, the injured party may
terminate this Agreement by written notice. In the event Lilly elects to

-9-

terminate this Agreement by reason of any default by ▇▇▇▇▇▇▇, the licenses
granted hereunder shall terminate.

Section 8.03. Residual Obligation Upon Termination: Termination of
--------------------------------------------------
this Agreement for any reason whatsoever willnot release or discharge Lilly or
▇▇▇▇▇▇▇ from the performance of any obligationor the payment of any debt which
may have previously accrued and remains to be performed, paid or discharged, at
the date of such termination. However, upon termination no further obligations
under this Agreement shall be incurred by Lilly or ▇▇▇▇▇▇▇.

Article IX
----------
Miscellaneous Provisions
------------------------

Section 9.02. Entire Agreement. This Agreement constitutes the complete and
------------------------------
definitive agreement of the parties on the subject matter hereof and supersedes,
cancels and annuls all prior or subsequent agreements, understandings and
undertakings relating to the subject matter hereof including, but, without
limiting the generality of the foregoing, any documents used by the parties in
making or accepting any offer. There are no verbal agreements, warranties,
representations or understandings affecting this Agreement, and all previous or
other negotiations, representations and understandings between Lilly and ▇▇▇▇▇▇▇
are merged herein.

Section 9.03. Severability. Each party agrees that, should any provision of
--------------------------
this Agreement be determined by a court of competent jurisdiction to violate or
contravene any applicable law or policy, such provision will be severed or
modified by the court to the extent necessary to comply with the applicable law
or policy, and such modified provision and the remainder of the provisions
hereof will continue in full force and effect. The parties specifically agree
that nothing in this Agreement is intended to require either party to take, or
not take, any action which would constitute a violation of any applicable law or
regulation, including but not limited to those regarding trade.

Section 9.04. Notices. Any notice required or permitted to be given under
---------------------
this Agreement shall be in writing and shall be deemed to have been sufficiently
given for all purposes if mailed by first class certified or registered mail,
postage prepaid, or sent by national overnight delivery

-10-

service, or by acknowledged facsimile. Unless otherwise specified in writing,
the mailing addresses of the parties shall be as follows:

For ▇▇▇▇▇▇▇:

▇▇▇▇▇▇▇ Laboratories Inc.
▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
Attention: ▇.▇. ▇▇▇▇▇▇, Vice President

For Lilly:

▇▇▇ ▇▇▇▇▇ and Company
Lilly ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: General Counsel

Section 9.05. Governing Law. This Agreement shall be governed by, and
----------------------------
construed in accordance with, the Laws of Indiana, excluding any choice of law
rules which may direct the application of the law of any other jurisdiction.

Section 9.06. Assignment. Except as expressly provided herein, neither
-------------------------
party may assign its rights and obligations under this Agreement except to an
Affiliate without the prior written consent of the other, except a party may
make such an assignment without the other party's consent in connection with any
merger or sale of all or substantially all of its assets to which this Agreement
relates. This Agreement shall be binding upon and inure to the benefit of the
successors and permitted assignees of the parties hereto.

Section 9.8. No Strict Construction. This Agreement has been prepared
------------------------------------
jointly and shall not be strictly construed against either party.

-11-

for such party's performance shall be extended for a period equal to the period
of such delay. such events shall include, without limitation, any labor strike
or lockout, act of God, war, fire, flood, embargo, act of any governmental
authority, riot, or any other unforeseeable cause or causes beyond the
reasonable control and without the fault or negligence of the party so affected.
The party so affected shall give prompt notice to the other party of such cause,
and shall take whatever reasonable steps are appropriate in the party's
discretion to relieve the effect of such cause as rapidly as possible.

Section 9.11. Currency. All references to "$" or "dollars" in this
-----------------------
agreement shall refer to United States dollars.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement by
their respective officers thereunto duly authorized.

▇▇▇▇▇▇▇ LABORATORIES, INC. ▇▇▇ LILLY AND COMPANY

By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ By: /s/▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
----------------------- -------------------------------
Title: President
Title: Executive Vice President
and Chief Financial Officer

By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
----------------------
Title: Vice President

-12-

Appendix A

Know-How shall mean all written information in the possession of Lilly regarding
the Compound of the types listed below reasonably useful to ▇▇▇▇▇▇▇ in
developing and manufacturing the compound. Lilly shall use its reasonable
efforts to locate and furnish to ▇▇▇▇▇▇▇ all material documents representing
Know-How. ▇▇▇▇▇▇▇ acknowledges that certain records may have been lost or
destroyed or otherwise be unavailable. Provided that Lilly has used its
reasonable efforts to locate such documents, Lilly shall have no further
obligation to ▇▇▇▇▇▇▇ with respect to such documents.

Marketing . Market research on GI markets prepared with respect to
the Compound

. Initial forecasts of market potential for the Compound

Toxicology . Written summary reports for the Compound

. LRL Summary Reports

Regulatory . Material regulatory documents relating to the Compound,
if any

-▇▇-

▇▇▇▇▇▇▇▇ ▇

Patent Status
-------------

LY353433
--------

Country Status Appln/Patent No.
--------------- ------ ----------------

Philippines Filed ▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇▇ Filed 52616
EPO* Filed 96301682.9
Israel Filed 117438
PCT Filed PCT/US96/03551
Taiwan Filed 84108549
South Africa Filed 96/1955
United States Filed 08/485956
India Filed 425/CAL/96

* Austria, Belgium, Switzerland, Denmark, France, Germany, Spain, Greece,
Italy, United Kingdom, Ireland, Lithuania, Latvia, Luxembourg, Netherlands,
Portugal, Sweden, Slovenia

EXHIBIT 10.81

LICENSE AGREEMENT
[LY 315535]

This License Agreement ("Agreement") is made as of the 4th day of December,
1996 by and between ▇▇▇ Lilly and Company, an Indiana corporation ("Lilly") and
▇▇▇▇▇▇▇ Laboratories Inc., a New Jersey corporation ("▇▇▇▇▇▇▇").

RECITALS
--------

1. Lilly and ▇▇▇▇▇▇▇ are in the business of discovering, developing and
marketing pharmaceutical products.

2. Lilly has discovered a compound internally designated as LY315535 (as
defined in Section 1.02 below, the "Compound") which may be useful in the
treatment of functional gastrointestinal disorders and other indications. Lilly
has previously engaged in certain research and development efforts with respect
to the Compound, but has concluded that future development efforts including
limited clinical trials could best be conducted by a company with a focus on
gastrointestinal products.

3. ▇▇▇▇▇▇▇ desires to license from Lilly certain rights of Lilly to the
Compound and to pursue development and commercialization of the Compound in the
Field and within the Territory (both as defined below), and Lilly is willing to
grant such license, all upon the terms and conditions set forth in this License
Agreement.

4. Concurrently with the execution of this Agreement, Lilly is attempting
to enter into a License Agreement with Societe de Conseils de Recherches et
d'Applications Scientifiques ("Third Party") pursuant to which Lilly is
licensing to Third Party certain rights to develop and commercialize the
Compound outside the Territory. ▇▇▇▇▇▇▇ and Third Party intend to enter into a
separate agreement among themselves providing for certain joint development
activities with respect to the Compound (the "Development Agreement").

AGREEMENT
---------

In consideration of the Recitals and the mutual covenants and agreements
set forth below, the parties agree as follows:

Article 1
---------
Definitions
-----------

When used in this Agreement, each of the following terms shall have the
meanings set forth below.

Section 1.01. "Affiliate" of a party hereto means any corporation or
-------------
business entity which at the time in question controls, is under common control
with, or is controlled by such party. As used herein, control shall mean the
ownership, directly or indirectly, of more than fifty percent (50%) of the
voting stock or similar interests of the corporation or business

-2-

entity or the ability to otherwise control the management of the corporation or
business entity.

Section 1.02. "Compound" means 2-di-n-propylamino-8-(isoxazol-5-yl)-
-------------
1,2,3,4-tetrahydronaphthalene and all pharmaceutically acceptable salts and
solvates.

Section 1.03. "Digestive System: means any portion of a human or animal's
-------------
body which is involved in the process of converting food into material suitable
for assimilation for synthesis of tissues or the liberation of energy or the
removal of waste from a human or animal's body. Such term thereby encompasses
all parts of a human or animal body which come in contact with food or waste
materials, from the mouth to the anus or urethra.

Section 1.04. "End User" means a wholesaler, distributor, pharmacy,
-------------
hospital, health care organization or patient.

Section 1.05. "Field" means products for Gastrointestinal Indications.
--------------

Section 1.06. "Gastrointestinal Indications" means disease states, such as
-------------
excess gastric acid secretion, inflammatory bowel disease, irritable bowel
syndrome, gastroesophagael reflux disease, esophagitis, dyspepsia, proctitis,
hemorrhoids, gastrointestinal ulceration, nausea and vomiting and constipation
and diarrhea, which are characterized by abnormalities of the Digestive System,
regardless of the mechanism involved in such disease states.

Section 1.07. "Know-How" means the items listed on the attached Appendix A
-------------
which are owned by or licensed to Lilly and reasonably useful to ▇▇▇▇▇▇▇ in
developing and manufacturing the Compound and Product.

Section 1.08. "Lilly Intellectual Property Rights" means all patent
-------------
rights, trade secret rights, and Know-How rights owned, licensed or otherwise
controlled by Lilly as of the date hereof which are useful in the Field,
encompass Compound and Product or are useful in preparing Compound and are
effective in the Territory, including all divisions, continuations,
continuations-in-part, reissuances, reexaminations, extensions, Supplementary
Protection Certificates, and any similar intellectual property rights, and all
counterparts thereof in the Territory. A list of all patent rights owned,
licensed or otherwise controlled by Lilly as of the date hereof and which are
encompassed hereunder is attached as Appendix B.

Section 1.09. "Net Sales" means with respect to a Product, the gross
-------------
amount invoiced by ▇▇▇▇▇▇▇, or any sublicensee, to an End User less the
following deductions:

1. Trade, quantity and cash discounts actually given or allowed;
2. Rebates, allowances, Medicaid and Medicare reimbursements, chargebacks
and similar deductions;
3. Any tax imposed on the sale, delivery or use of the product; and

-3-

4. Allowed or credits for returned goods or rejections of any Product which
is unsalable.

Section 1.10. "Phase II Clinical Trial" means a large scale clinical study
-------------
conducted in patients to establish Product efficacy in the Field and to support
Product Registration.

Section 1.11. "Product" means any pharmaceutical composition for use as a
-------------
therapeutic or diagnostic product that incorporates the Compound.

Section 1.12. "Territory" means the United States and its territories
-------------
(Puerto Rico, Guam), Canada and Mexico.

Article II
----------
License
-------

Lilly grants to ▇▇▇▇▇▇▇ an exclusive license to make, have made, use or
sell for use in the Field within the Territory the Compound and Product pursuant
to all Lilly Intellectual Property Rights. With respect to any patent rights
licensed hereunder, such license shall be limited solely to those patent claims
necessary to provide ▇▇▇▇▇▇▇ with the ability to make, have made, use or sell
Product in the Field within the Territory and shall, further, be limited solely
to the right to make, have made, use or sell Product in the Field within the
Territory. Such license shall include the right of ▇▇▇▇▇▇▇ to sublicense,
consistent with the terms of this Agreement. All terms and provisions of this
Agreement shall apply to each sublicense to the same extent as they apply to
▇▇▇▇▇▇▇, and ▇▇▇▇▇▇▇ shall guarantee performance by its sublicensee of all
obligations imposed under the terms of this Agreement.

Article III
-----------
Payments and Royalties
----------------------

Section 3.01. Signing and Milestone Payments.
---------------------------------------------

(a) As consideration for the licenses granted hereunder, ▇▇▇▇▇▇▇ shall pay
Lilly by wire transfer loan account designated by Lilly the following
account at the following times:

(i) Upon execution of this Agreement $1 million

(ii) Upon commencement of the first Phase $2 million
III Clinical Trial for a Product:

(iii) Upon acceptance for filing by the FDA of $2 million

-4-

the first New Drug Application (or its
equivalent) for a Product:

(b) It is anticipated that ▇▇▇▇▇▇▇ and Third Party will, pursuant to the
Development Agreement or otherwise, jointly conduct certain development
efforts and Clinical Trials. If pursuant to such arrangements one or
more of the Clinical Trials referred to above shall be conducted by
Third Party, with ▇▇▇▇▇▇▇ to utilize the results of such trials, then
the Clinical Trials referred to above as milestones for which payments
may be due shall mean such Clinical Trials conducted by Third Party.

(c) All payments described above shall be made within thirty (30) days of
the relevant event, except for the payment described in (a)(i), which
shall be made upon signing of this agreement. Any payment not made when
due shall bear interest at the United States prime rate on the due date
as published in the Wall Street Journal, plus six percent (6%).
-------------------

Section 3.02. Royalty. As additional consideration for the licenses
-----------------------
granted herein, ▇▇▇▇▇▇▇ shall pay to Lilly a royalty equal to 8% of Net Sales of
Products in the Territory. Royalties shall be reported and paid quarterly in
accordance with Article VII of this Agreement.

Article IV
----------
Prosecution and Infringement of Intellectual Property Rights
------------------------------------------------------------

Section 4.01 Patent Term Extensions and Supplementary Protection
-----------------------------------------------------------------
Certificates. Lilly upon request of ▇▇▇▇▇▇▇ shall apply for (and ▇▇▇▇▇ ▇▇▇▇▇▇▇ a
------------
license under) patent term extensions, Supplementary Protection Certificates or
functional equivalents thereof, in any jurisdiction within the Territory where
such items are permissible, for any Lilly Intellectual Property Rights licensed
to ▇▇▇▇▇▇▇ hereunder. ▇▇▇▇▇▇▇ will provide Lilly with all material and
information as may be necessary to obtain any of the aforesaid rights.

Section 4.02. Prosecution and Maintenance of Licensed Patents.
--------------------------------------------------------------

(a) Upon execution of this Agreement, Lilly shall provide to ▇▇▇▇▇▇▇
Appendix B attached hereto which identifies all pending applications and
patents in the Territory which are encompassed in the Lilly Intellectual
Property Rights.

(b) Lilly shall prosecute any pending applications of which it is the owner
that are encompassed in the Lilly Intellectual property Rights and maintain
any patents that have issued or will issue thereon in full force and effect
for the term of such patent. Should, during the course of prosecution of
any pending claims, an official action rejecting the claims require that an
amendment be made or action be taken which would limit or substantially
change the scope of any license

-5-

hereunder, Lilly will timely inform ▇▇▇▇▇▇▇ in writing. Lilly shall consult
▇▇▇▇▇▇▇ before responding to any such official action, and allow ▇▇▇▇▇▇▇ to
assist in the prosecution of such claims or, at Lilly's option, allow
▇▇▇▇▇▇▇ the opportunity at its time and expense to prosecute such claims
to its satisfaction.

Section 4.03. Costs of Prosecution and Maintenance of Patents. Lilly
--------------------------------------------------------------
shall bear all costs incurred in filing, prosecuting and maintaining all patents
and patent applications encompassed within the Intellectual Property Rights,
provided, however, that ▇▇▇▇▇▇▇ shall pay one-half (1/2) of all reasonable
external expenses incurred by Lilly while prosecuting and maintaining such
patents and patent applications. External expenses will include patent office
fees and taxes in connection with the prosection and maintenance of any patent
or patent application and the fees of any patent attorneys or agents, external
of Lilly, in connection with the ex parte prosection and maintenance thereof.
-- -----
The allocation of such expenses will occur on an annual basis at the end of the
last quarter of each calendar year, at which time Lilly will provide ▇▇▇▇▇▇▇
with an itemized list of external expenses denominated in United States dollars
incurred during the previous annual period. ▇▇▇▇▇▇▇ will then reimburse Lilly's
expenses within sixty (60) days of the date of receipt of this itemized list.
Notwithstanding the foregoing, Lilly may, at its sole discretion, choose not to
prosecute or cease to maintain a patent or patent application in any country as
it so desires and to the extent that Lilly chooses not to prosecute or ceases to
maintain such patent or patent application Lilly shall not be responsible for
any patent costs associated with prosecuting and/or maintaining the patent or
patent application in such country. If ▇▇▇▇▇▇▇ desires to prosecute or maintain
such patent or patent application, ▇▇▇▇▇▇▇ may do so at its own expense;
however, under these circumstances, Lilly would ▇▇▇▇▇ ▇▇▇▇▇▇▇ all of its patent
rights associated which such patent in such country. Similarly, upon written
notice to Lilly, ▇▇▇▇▇▇▇ may elect not to share in the prosecution or
maintenance costs as described in this Section 4.03 related to a patent or
patent application in a particular country; however, upon such election any
rights that ▇▇▇▇▇▇▇ has in such patent in such country would be granted to
Lilly.

Section 4.04. Option by ▇▇▇▇▇▇▇ to Discontinue License. ▇▇▇▇▇▇▇, at its
-------------------------------------------------------
option, may elect to discontinue the license granted and surrender all rights
hereunder as to any patent on a country-by-country basis. Such election must be
made by thirty (30) days written notice by simultaneous facsimile transmission
and certified mailing, and, with respect to the surrender of ▇▇▇▇▇▇▇' rights,
will be effective as of the date of mailing. In the event such an election is
made, Lilly's obligations under Section 4.01 and 4.02 and ▇▇▇▇▇▇▇' obligations
under Section 4.03 will terminate thirty (30) days from the date of mailing with
respect to the specific patent on which the election is made.

-6-

infringement or suspected infringement to be terminated. Each party, at its
option, may elect to participate in or commence such a legal action. In the
event of a joint action in which both parties agree to participate, the parties
will share in the costs and the recovery of the agreed upon course of action in
a manner to be agreed upon. Failing agreement on a course of action to ▇▇▇▇▇
infringement, potential infringement or suspected infringement within sixty (60)
days of the time such infringement, potential infringement or suspected
infringement becomes known to both parties, either party shall have the right,
at its own expense, to initiate and prosecute an action against the infringer
and shall retain whatever damages are recovered. In the event ▇▇▇▇▇▇▇ is unable
to initiate and prosecute such action solely in its own name, Lilly will execute
(and cause its Affiliates to execute) all documents necessary for ▇▇▇▇▇▇▇ to
initiate and prosecute such action. Neither party will enter into any
settlement of any action referred to in this Section without the other party's
prior consent, which consent shall not be unreasonably withheld.

Section 4.06. Reexamination and Reissue. Lilly shall defend in a
----------------------------------------
reasonable manner any patent encompassed within the Lily Intellectual Property
Rights in any reexamination or reissue proceeding in the United States Patent
and Trademark Office and the applicable foreign equivalent. Before Lilly
initiates a reissue proceeding, or before either party initiates a reexamination
proceeding, the parties shall consult as to the desirability or necessity of
such a proceeding. Such proceedings will not be abandoned prior to a final
decision of the Patent Office Board of Appeals or Patent Office Board of
Interferences and the applicable foreign equivalent without the consent of
▇▇▇▇▇▇▇, which consent will not be unreasonably withheld taking into
consideration, inter alia, the merits of the action of the Patent and Trademark
Office and the applicable foreign equivalent, priority dates provable by any
interference party (should an interference be involved), and the technological
and commercial important of the subject matter of the claims of the application
or patent involved expenses shall be borne as provided in Section 4.03.

Article V
---------
Disclosure of Agreement
-----------------------

Section 5.01. Disclosure of Agreement. Except as provided below, neither
--------------------------------------
▇▇▇▇▇▇▇ or Lilly shall release any information to any third party with respect
to the existence and terms of this Agreement without the prior written consent
of the other party to this Agreement, except that ▇▇▇▇▇▇▇ may disclose the
existence (but not financial terms) of this Agreement to Third Party.

-7-

of the proposed release. The notice shall include the exact text of the proposed
release, the time and manner of the release, and the basis for such party's
belief that disclosure is required. At the other party's request and before the
release, the party desiring to release information shall consult with the other
party on the necessity for the disclosure and the text of the proposed release.
In no event shall a release include information regarding the existence of terms
of this Agreement that is not required by law or governmental regulation without
the consent of the other party.

Article VI
----------
Certain Undertakings
--------------------

Section 6.02. ▇▇▇▇▇▇▇ Efforts. ▇▇▇▇▇▇▇ hereby agrees to use its best
------------------------------
efforts to develop and commercialize Products within the Territory. ▇▇▇▇▇▇▇ may
abandon development efforts for the Compound at any time if in the reasonable
judgment of ▇▇▇▇▇▇▇ further development efforts are not justified. If ▇▇▇▇▇▇▇
so abandons development, it shall upon request, assign to Lilly or Lilly's
designee all intellectual property, records, data, clinical trial results and
other information relating to the Compound in return for which Lilly or its
designee shall pay to ▇▇▇▇▇▇▇ an amount equal to ▇▇▇▇▇▇▇' total development
costs (including all out of pocket costs and reasonable internal costs).
Furthermore, upon execution of this Agreement, ▇▇▇▇▇▇▇ shall assume all
responsibilities for all adverse event reporting, annual reporting and any other
reporting responsibilities to regulatory agencies in the Territory.

-8-

provide facilities in connection with providing technical assistance.

Article VII
-----------
Accounting
----------

Section 7.01. Sales and Royalty Reports. ▇▇▇▇▇▇▇ shall deliver to Lilly
----------------------------------------
within sixty (60) days after the end of each calendar quarter a written
accounting of ▇▇▇▇▇▇▇' Net Sales and the royalty payment due to Lilly for such
quarter. Such quarterly reports shall be in English and include the Net Sales
of products on a country-by-country basis (expressed in United States dollars or
computed under the provisions of Section 7.04 hereof), a sales forecast for each
quarter of the current calendar year, and contain such other information as
Lilly may from time to time reasonably request. Annually, by October 1, ▇▇▇▇▇▇▇
shall deliver to Lilly a sales forecast, by quarter, for the subsequent calendar
year. All sales and royalty reports shall be directed to ▇▇▇ ▇▇▇▇▇ and Company,
Attn: Royalty Administration, D.C. ▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇,
▇▇▇▇▇▇▇ ▇▇▇▇▇. In the event ▇▇▇▇▇▇▇ makes sales of Products(s) to persons other
than End Users, ▇▇▇▇▇▇▇ shall require such persons to provide ▇▇▇▇▇▇▇ with such
information as Lilly may reasonably request to permit Lilly to calculate and
verify Net Sales and royalties due.

Section 7.03. Audits. ▇▇▇▇▇▇▇ shall keep accurate records in sufficient
---------------------
detail to enable to amounts due to Lilly hereunder to be determined. During the
term of this Agreement and for two (2) years after its termination, Lilly shall,
not more than once each year and upon written notice, have the right, at its
expense, to audit the books and records of ▇▇▇▇▇▇▇ for the purpose of
determining the accuracy of royalty payments. If ▇▇▇▇▇▇▇ has underpaid a
royalty amount due under this Agreement by more than five percent (5%), ▇▇▇▇▇▇▇
shall, in addition to paying any royalties due, also reimburse Lilly for the
cost of such audit.

Section 7.04. Exchange Rates and Currency Translation. All payments to be
------------------------------------------------------
made by ▇▇▇▇▇▇▇ to ▇▇▇▇▇ under this Agreement shall be made and reported in
United States dollars. The rate of exchange to be used in computing the amount
of Net Sales and the United States dollars due Lilly shall be calculated using
▇▇▇▇▇▇▇' then current standard exchange rate methodology, which methodology is
used by ▇▇▇▇▇▇▇ in the translation of its foreign currency operating results for
external reporting, is consistent with United States generally accepted
accounting principles and is reviewed and approved by ▇▇▇▇▇▇▇' independent
certified public accountants.

Section 7.05. Withholding Taxes. ▇▇▇▇▇▇▇ shall have no liability for any
--------------------------------
income

-9-

taxes levied against Lilly on account of royalties paid hereunder. If laws or
regulations require that any such taxes be withheld by ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ shall
deduct such taxes from the payment due Lilly, pay the taxes so withheld to the
proper taxing authority, and send proof of payment to Lilly annually within
ninety (90) days of the first day of the year following such payment. If Lilly
desires to obtain a refund of any taxes so withheld and paid to a taxing
authority, ▇▇▇▇▇▇▇ shall cooperate in the pursuit of such refund.

Article VIII
------------
Term and Termination
--------------------

Section 8.01. Term. This Agreement shall become effective on the date
-------------------
hereof, and shall remain in effect until the later of either: (i) the life of
the last to expire of the patents encompass in the Lilly Intellectual Property,
or (ii) fifteen (15) years from the date hereof. Upon termination of this
Agreement as set forth in this Section 8.01, the licenses granted to ▇▇▇▇▇▇▇
hereunder shall be deemed to be paid up in full.

Section 8.03. Residual Obligation Upon Termination. Termination of this
---------------------------------------------------
Agreement for any reason whatsoever will not release or discharge Lilly or
▇▇▇▇▇▇▇ from the performance of any obligation or the payment of any debt which
may have previously accrued and remains to be performed, paid or discharged, at
the date of such termination. However, upon termination, no further obligations
under this Agreement shall be incurred by Lilly or ▇▇▇▇▇▇▇.

Article IX
----------
Miscellaneous Provisions
------------------------

-10-

are merged herein.

For ▇▇▇▇▇▇▇:

For Lilly:

▇▇▇ ▇▇▇▇▇ and Company
Lilly ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: General Counsel

Section 9.5. Governing Law. This Agreement shall be governed by, and
---------------------------
construed in accordance with, the laws of Indiana, excluding any choice of law
rules which may direct the application of the law of any other jurisdiction.

Section 9.6. Assignment. Except as expressly provided herein, neither
------------------------
party may assign its rights and obligations under this Agreement except to an
Affiliate without the prior written consent of the other, except a party may
make such an assignment without the other party's consent in connection with any
merger or sale of al or substantially all of its assets to which this Agreement
relates. This Agreement shall be binding upon and inure to the benefit of the
successors and permitted assignees of the parties hereto.

-11-

approval shall not unreasonably be withheld, and whenever in this Agreement
provisions are made for one party to object to or disapprove a matter, such
objection or disapproval shall not unreasonably be exercised.

Section 9.8. No Strict Construction. This Agreement has been prepared
------------------------------------
jointly and shall not be strictly construed against either party.

Section 9.11. Currency. All references to "$" or "dollars" in this
-----------------------
agreement shall refer to United States dollars.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement by
their respective officers thereunto duly authorized.

▇▇▇▇▇▇▇ LABORATORIES INC. ▇▇▇ LILLY AND COMPANY

By: /s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
--------------------- -------------------------
Title: Vice President Title: Executive Vice President
and Chief Financial Officer

By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
-----------------------
Title: Vice President

-12-

Appendix A

Marketing . Market research on GI markets prepared with respect to
the Compound

. Initial forecasts of market potential for the Compound

Toxicology . Written summary reports for the Compound

Project Management
Status Reports . For the Compound for the 2 years prior to
discontinuation of Lilly's development effort

Regulatory . CTX for the Compound

. All other material regulatory documents relating to the
Compound, including any and all clinical data

-▇▇-

▇▇▇▇▇▇▇▇ ▇
----------

Patent Position
---------------

LY315535
--------

Compound USSN 07/850,136

Use in Treating IBS US 5,434,174

Intermediates to Compound US 5,389,687
US 5,426,229
US 5,286,753
US 5,426,226
US 5,434,174

EXHIBIT 10.81 LICENSE AGREEMENT [LY213829]

Document Metadata

Document Metadata

Table of Contents